Navigation Links
Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
Date:9/11/2008

SEATTLE, Sept. 11 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN), today announced that the Opposition Division (OD) of the European Patent Office (EPO) has revoked Genentech and Biogen Idec's European Patent 1176981, in its entirety. This patent was generally directed to the use of an anti-CD20 antibody for the treatment of rheumatoid arthritis (RA). The revocation was the result of an opposition proceeding brought by Trubion and several other parties.

The OD, presiding in oral proceedings on Thursday, Sept. 11, 2008, ruled that the patent as granted did not meet the requirements for patentability under the European Patent Convention. Genentech and Biogen Idec have the right to appeal the decision.

"We are extremely pleased with the EPO's decision as it supports the continued development of new and innovative therapies that have the potential to improve patient outcomes for autoimmune and inflammatory diseases. Continued innovation will ultimately provide patients with more effective, convenient, and safer therapies," said Peter Thompson, M.D., FACP, president, chief executive officer and chairman of Trubion.

Forward Looking Statements

Certain statements in this release may constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933. These statements include, but are not limited to those related to the expansion of Trubion's product pipeline and its development of new product candidates. These statements are based on current expectations and assumptions regarding future events and business performance and involve certain risks and uncertainties that could cause actual results to differ mate
'/>"/>

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
2. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
3. Trubion Announces Presentations at April/May Investor Conferences
4. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
5. Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
6. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
7. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
8. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
9. Dr. Paul Korner Joins Ferring Pharmaceuticals as Vice President, Medical Affairs
10. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
11. VIA Pharmaceuticals to Host Investor Science Briefing on the Role of Inflammation in Cardiovascular Disease on Tuesday, September 16
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... BIRMINGHAM, Ala., July 29, 2015 /PRNewswire/ ... the nation,s largest providers of post-acute healthcare services, ... reported its results of operations for the second ... second quarter was characterized by strong volume growth ... our Adjusted EBITDA," said Jay Grinney, President and ...
(Date:7/29/2015)... Research and Markets ... the "Global Biosimilars Market, 2015 - 2025" ... Global Biosimilars Market, 2015 - 2025, report provides ... market. With the blockbuster biologics losing patent protection ... are being viewed as viable substitutes to the ...
(Date:7/29/2015)... 2015  Therapath Neuropathology ( www.Therapath.com ), a ... VA and Military Medical centers both domestically and ... and Sweat Gland Nerve Fiber Density (SGNFD) for ... ). Demonstration of a reduction ... punch skin biopsy is a highly sensitive and ...
(Date:7/29/2015)... ... ... The third Medical Innovation Impact Index (MI3) Alert considers FDA processes for ... current system received a score of 0 (range -10 to +10) for its impact ... Fairleigh Dickinson University’s ( FDU ) Rothman Institute of Innovation and Entrepreneurship. Several changes ...
Breaking Biology Technology:HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25HealthSouth Reports Results for Second Quarter 2015 26HealthSouth Reports Results for Second Quarter 2015 27HealthSouth Reports Results for Second Quarter 2015 28HealthSouth Reports Results for Second Quarter 2015 29HealthSouth Reports Results for Second Quarter 2015 30HealthSouth Reports Results for Second Quarter 2015 31HealthSouth Reports Results for Second Quarter 2015 32HealthSouth Reports Results for Second Quarter 2015 33HealthSouth Reports Results for Second Quarter 2015 34HealthSouth Reports Results for Second Quarter 2015 35HealthSouth Reports Results for Second Quarter 2015 36
... 28 , - New ... , Bial-Portela & CA, S.A., ... Portela), and Eisai Europe Limited (London; Chairman & CEO ... President &,CEO: Haruo Naito), today announced that the novel ...
... scientists have unlocked the physics of the perfect pizza ... generation of micro motors thinner that a human hair. ... by Associate Professor James Friend and Senior Lecturer Leslie ... team from Monash,s Micro/Nanophysics Research Laboratory, then calculated how ...
... -- Encorium Group, Inc. (Nasdaq: ... (CRO) that provides design, development, and management capabilities ... of the world,s leading pharmaceutical companies, today announced ... Annual Vaccine Industry Excellence Award for Best Contract ...
Cached Biology Technology:Novel Once Daily Anti-Epileptic Zebinix(R) Approved in the European Union 2Novel Once Daily Anti-Epileptic Zebinix(R) Approved in the European Union 3Novel Once Daily Anti-Epileptic Zebinix(R) Approved in the European Union 4Novel Once Daily Anti-Epileptic Zebinix(R) Approved in the European Union 5Novel Once Daily Anti-Epileptic Zebinix(R) Approved in the European Union 6Novel Once Daily Anti-Epileptic Zebinix(R) Approved in the European Union 7Novel Once Daily Anti-Epileptic Zebinix(R) Approved in the European Union 8Novel Once Daily Anti-Epileptic Zebinix(R) Approved in the European Union 9Pizza tossing art unlocks secrets of tiny motors 2Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award 2Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award 3Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award 4
(Date:7/8/2015)... , N.J. and NEW YORK , ... and Guidepoint today announced BD & ... healthcare companies with free access to Guidepoint,s expert network ... start-ups that are developing cutting-edge technologies to improve healthcare ... dedicated Guidepoint research manager, each start-up entrepreneur will be ...
(Date:7/7/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") a biometric ... revised version of one of its first 30 second commercials will ... New York , Chicago , ... metro areas.    , , , , ... the cards in your wallet and keep your identity secure. ...
(Date:6/30/2015)... HATFIELD, Pa. , June 30, 2015 ... joined the company as CEO to help further develop ... a wealth of partnering experience, having spent much of ... companies including Therakine, Amgen, Baxter Bioscience, and Johnson & ... a focus on Technology and Biotech Corporate Finance. He ...
Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... established HPV types. Cancerous human papillomavirus (HPV) viruses are the ... to 100% of cervical tumors. Cervical cancer and ... virus using standard techniques can sometimes give a negative result ... In a new study published in Virology , ...
... critically endangered large primate known as the drill ( ... few critical habitat areas in Cameroon, according to a ... Zoo,s Institute for Conservation Research. The study highlights ... area becomes ever more fragmented by human disturbance. ...
... infectious diseases meeting of the American Society for Microbiology ... Antimicrobial Agents and Chemotherapy (ICAAC) will be held September ... Colorado. Known as the preeminent world meeting for ... infectious diseases and anti-infective therapy, ICAAC has also traditionally ...
Cached Biology News:53rd ICAAC: Media registration now open 2
... for RNA aptamer screening and binding optimization ... Paraflo microfluidic on-chip synthesis platform. These microarrays ... DNA/RNA Aptamer Microarray Service. Probe ... Microarray contains greater than 1500 known aptamer ...
... RNA aptamer screening and binding optimization and ... microfluidic on-chip synthesis platform. Thousands of customer ... and LC Sciences can provide assistance with ... as part of our comprehensive DNA/RNA Aptamer ...
... (GST) is commonly used as a fusion ... (1). The GSTTag sequence has been reported ... cases the solubility of its fusion partners. ... form, GSTTag fusion proteins can be purified ...
... from the C-terminal end of the mouse retinoic acid receptor beta (RAR*). ... 448 of RAR*. The sequence of PEP-005 is (amino to carboxy ... - S - S - V - E - N - S ... - L - L - Q (The N-terminal cysteine has been ...
Biology Products: